Expression of the ATDC (ataxia telangiectasia group D-complementing) gene in A431 human squamous carcinoma cells

✍ Scribed by Keith R. Laderoute; A. Merrill Knapp; Christopher J. Green; Robert M. Sutherland; Leon N. Kapp

• Publisher: John Wiley and Sons
• Year: 1996
• Tongue: French
• Weight: 922 KB
• Volume: 66
• Category: Article
• ISSN: 0020-7136
• DOI: 10.1002/(sici)1097-0215(19960611)66:6<772::aid-ijc11>3.0.co;2-5

✦ Synopsis

The ATDC gene was originally identified by its ability to complement the radiosensitivity defect of an ataxia telangiectasia (AT) fibroblast cell line. Because hypersensitivity to ionizing radiation is an important feature of the AT phenotype, we reasoned that ATDC may function generally in the suppression of radiosensitivity. Previous work in our laboratory focused on radiosensitization mechanisms in human squamous carcinoma (SC) cells, especially A43 I cells. To establish a basis for investigating the role of ATDC in radiation-responsive signaling pathways in human SC cells, we characterized ATDC message and protein expressions in A43 I cells. ATDC message expression was also compared among human epidermoid cells (A43 I cells, HaCaT spontaneously immortalized human keratinocytes and normal human epidermal keratinocytes) and a normal human fibroblast cell line (LM217). We made the following major observations: (i) the relative abundance of ATDC message is substantially higher in the epidermoid cells than in the fibroblast cell line, which has a message level comparable to those reported for other fibroblast lines; (ii) ATDC is constitutively phosphorylated on serinekhreonine in A43 I cells; (iii) in A43 I cells, ATDC is a substrate for the serine/threonine protein kinase C (PKC) but not the epidermal growth factor (EGF) receptor tyrosine kinase; and (iv) EGF decreases ATDC message and protein expressions in A431 cells after a 24-hr exposure. The phosphorylation studies suggest that the ability of ATDC to modulate cellular radiosensitivity may be mediated in part through a PKC signaling pathway.